SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05938-5 ↗At a glance
Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Zihao Zhao and 7 co-authors. Institution: Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China. Major MEDLINE topics: Mechanistic Target of Rapamycin Complex 1, Signal Transduction, Stomach Neoplasms. Cited 3 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Postgraduate Research and Practice Innovation Program of Jiangsu Province, National Natural Science Foundation of China, Science and Technology Bureau of Nantong.
Abstract (original language)
BACKGROUND: The SCY1-like (SCYL) family has been reported to be closely related to cancer metastasis, but it has not been reported in gastric cancer (GC), and its specific mechanism is not clear. METHODS: We utilized databases like Deepmap, TCGA, and GEO to identify SCYL1's role in GC. Clinical samples were analyzed for SCYL1 expression and its correlation with patient prognosis. In vitro and in vivo experiments were conducted to assess SCYL1's function in GC cell migration, invasion, and autophagy. RESULTS: SCYL1 showed an increased expression in GC tissues, which correlated with a negative prognosis. In vitro experiments demonstrated that SCYL1 promotes GC cell migration and invasion and inhibits autophagy. GSEA indicated an inverse relationship between SCYL1 and autophagy, while a direct relationship was observed with the mTORC1 signaling pathway. Knockdown of SCYL1 enhanced autophagy, while activation of mTORC1 reversed this effect. CONCLUSIONS: SCYL1 is a significant contributor to GC progression, promoting metastasis by activating the mTORC1 signaling pathway and inhibiting autophagy. These findings suggest SCYL1 as a potential therapeutic target for GC treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China.
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, China.
- Nantong Key Laboratory of Gastrointestinal Oncology, Nantong, 226001, China.
- Qidong People's Hospital, Nantong, 226001, China.
- Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China. xuewanjiang@ntu.edu.cn.
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, China. xuewanjiang@ntu.edu.cn.
Funding
- Postgraduate Research and Practice Innovation Program of Jiangsu Province
- National Natural Science Foundation of China
- Science and Technology Bureau of Nantong
- Natural Science Foundation of Nantong Municipality
- Natural Science Foundation of the Jiangsu Province
- Fundation of Jiangsu Province Research Hospital
Cite
APA
Zhao, Z., Liu, J., Gao, X., Chen, Z., Hu, Y., Chen, J., Zang, W., & Xue, W. (2024). SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05938-5
Vancouver
Zhao Z, Liu J, Gao X, Chen Z, Hu Y, Chen J, et al. SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05938-5
BibTeX
@article{Zhao2024,
author = {Zhao, Zihao and Liu, Jinlong and Gao, Xian and Chen, Zhuzheng and Hu, Yilin and Chen, Junjie and Zang, Weijie and Xue, Wanjiang},
title = {SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05938-5}
}
EUVIMED